Back to results
US 11,230,599 B2Granted
Tumor mutational load
AssigneeMemorial Sloan Kettering Cancer Center
InventorsTimothy A. Chan, Diego Chowell Puente, Robert M. Samstein, Luc Morris
Life of this patent
Estimating the term…
Abstract
The present invention encompasses the discovery that the likelihood of a favorable response to cancer immunotherapy for a wide range of different cancers can be predicted through definition of a tumor mutational load threshold for the tumor (and/or the relevant immunotherapy).
Claims16
A method comprising:
- administering immunotherapy to a subject with a tumor that displays a tumor mutational load, wherein the tumor mutational load, when measured after the subject has received immunotherapy, is above a threshold that has been correlated with a statistically significant probability of responding to immunotherapy, wherein the tumor mutational load threshold is selected from the group consisting of:
- Cancer Type
- Threshold
- Bladder Cancer
- About 7 to about 27
- Breast Cancer
- About 1 to about 14
- Esophagogastric Cancer
- About 1 to about 21
- Glioma
- About 1 to about 15
- Head and Neck Cancer
- About 1 to about 18
- Melanoma
- About 1 to about 31
- Non-Small Cell Lung Cancer
- About 1 to about 29 and
- Renal Cell Carcinoma
- About 1 to about 12
- and wherein the administered immunotherapy is one or more of a PD-1 or PD-L1 blockade therapy or a CTLA-4 blockade therapy.
17 more elements
A method comprising:
- administering immunotherapy with an immune checkpoint modulator to a subject who displays HLA class I heterozygosity in a tumor, wherein the immunotherapy is one or more of a PD-1 or PD-L1 blockade therapy or a CTLA-4 blockade therapy.
A method comprising:
- administering immunotherapy to a subject with a tumor that displays a tumor mutational load above a threshold that has been correlated with a statistically significant probability of responding to immunotherapy and displays HLA class I heterozygosity, wherein the tumor mutational load threshold is selected from the groups consisting of:
- Cancer Type
- Threshold
- Bladder Cancer
- About 7 to about 27
- Breast Cancer
- About 1 to about 14
- Esophagogastric Cancer
- About 1 to about 21
- Glioma
- About 1 to about 15
- Head and Neck Cancer
- About 1 to about 18
- Melanoma
- About 1 to about 31
- Non-Small Cell Lung Cancer
- About 1 to about 29 and
- Renal Cell Carcinoma
- About 1 to about 12
- and wherein the immunotherapy is a combination of one or more of a PD-1 blockade therapy and a CTLA-4 blockade therapy.
17 more elements
Dependencies are inferred from the claim text.